Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis

Affiliations

• ¹ Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
• ² Department of Clinical Haematology, University College London Hospital, London, United Kingdom.
• ³ Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
• ⁴ Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, United Kingdom.
• ⁵ Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
• ⁶ Centre for Clinical Haematology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
• ⁷ Department of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.
• ⁸ Department of Histopathology, University College London Hospital, London, United Kingdom.
• ⁹ Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
• ¹⁰ Cancer Research UK and UCL Cancer Trial Centre, UCL Cancer Institute, University College London, London, United Kingdom.
• ¹¹ Department of Haematology, Barking Havering and Redbridge University Hospital NHS Trust, Romford, United Kingdom.
• ¹² Clatterbridge Cancer Centre, Liverpool University Hospitals, Liverpool, United Kingdom.
• ¹³ School of Medicine, University of Nottingham, Nottingham, United Kingdom.